Download presentation
Presentation is loading. Please wait.
Published byCatherine Watson Modified over 9 years ago
1
estrogen + progesterone Watch for thrombus formation, avoid if px has estrogen- dependent neoplasm risk factors
2
raloxifene Selective estrogen receptor modulator (SERM)
3
alendronate bisphophonate
4
risedronate bisphophonate
5
zoledronate Bisphophonate good treatement for malignant hypercalcemia
6
pamidronate Bisphophonate good treatement for malignant hypercalcemia
7
ibandronate bisphophonate Too weak to prevent non- vertebral fractures
8
denosumab RANKL antibody For osteoporosis
9
teriparatide(hPTH 1-34) Bone anabolic agent
10
hPTH 1-84 (investigational) Bone anabolic agent Not approved b/c of hypercalcemia
11
fluoride (investigational) Bone anabolic agent
12
aluminum hydroxide oral phosphate binder Avoid b/c of aluminum toxicity
13
calcium carbonate/acetate oral phosphate binder Watch for hypercalcemia
14
sevelamer oral phosphate binder Best treatment
15
ergocalciferol Vitamin D2: equivalent biological activity to D3
16
calcifediol 25(OH)D
17
calcitriol 1,25(OH) 2 D 2
18
doxercalciferol Synthetic vitamin D analogue, activated in liver
19
paricalcitol Synthetic vitamin D analogue
20
cinacalcet calcimimetic—decreases PTH secretion
21
calcium gluconate given via IV
22
calcium chloride given via IV
23
calcium carbonate given PO
24
calcium citrate given PO
25
calcium lactate given PO
26
potassium phosphate Inorganic phosphate
Similar presentations
© 2025 SlidePlayer.com. Inc.
All rights reserved.